These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28595667)

  • 1. EXPERIENCES IN ADAPTING EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT RAPID REVIEWS TO INFORM LOCAL DECISION MAKING.
    Macpherson K; Thompson L
    Int J Technol Assess Health Care; 2017 Jan; 33(2):155-159. PubMed ID: 28595667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality].
    Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
    Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
    Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involving stakeholders and developing a policy for stakeholder involvement in the European network for health technology assessment, EUnetHTA.
    Nielsen CP; Lauritsen SW; Kristensen FB; Bistrup ML; Cecchetti A; Turk E;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():84-91. PubMed ID: 20030895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit.
    Halmesmäki E; Pasternack I; Roine R
    Health Res Policy Syst; 2016 Apr; 14():25. PubMed ID: 27044400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
    Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
    Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Healthcare Improvement Scotland evidence note rapid review process: providing timely, reliable evidence to inform imperative decisions on healthcare.
    McIntosh HM; Calvert J; Macpherson KJ; Thompson L
    Int J Evid Based Healthc; 2016 Jun; 14(2):95-101. PubMed ID: 27058251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary survey on the influence of rapid health technology assessments.
    Hailey D
    Int J Technol Assess Health Care; 2009 Jul; 25(3):415-8. PubMed ID: 19619362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA.
    Kristensen FB; Lampe K; Chase DL; Lee-Robin SH; Wild C; Moharra M; Garrido MV; Nielsen CP; Røttingen JA; Neikter SA; Bistrup ML;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():1-8. PubMed ID: 20030885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Information specialist collaboration in Europe: collaborative methods, processes, and infrastructure through EUnetHTA.
    Waffenschmidt S; van Amsterdam-Lunze M; Gomez RI; Rehrmann M; Harboe I; Hausner E
    Int J Technol Assess Health Care; 2020 Oct; 37():e20. PubMed ID: 33081862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
    Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
    Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Collaboration in Health Technology Assessment (HTA): goals, methods and outcomes with specific focus on medical devices.
    Erdös J; Ettinger S; Mayer-Ferbas J; de Villiers C; Wild C
    Wien Med Wochenschr; 2019 Sep; 169(11-12):284-292. PubMed ID: 30725440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013.
    Charokopou M; Majer IM; Raad Jd; Broekhuizen S; Postma M; Heeg B
    Value Health; 2015 Mar; 18(2):284-91. PubMed ID: 25773564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.
    Kleijnen S; Fathallah M; van der Linden MW; Vancraeynest P; Dahmani B; Timoney A; De Boer A; Leufkens HG; Goettsch WG
    Value Health; 2015 Jul; 18(5):663-72. PubMed ID: 26297095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adaptation of health technology assessment reports: identification of the need for, and development of, a toolkit to aid the process.
    Turner S; Chase DL; Milne R; Cook A; Hicks NJ; Rosten C; Payne L; Coles S; Bell E;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():28-36. PubMed ID: 20030888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.